LINCOMED 300- lincomycin injection Bimeda, Inc.

LincoMed® 300 (lincomycin injection)

For use in swine weighing 300 pounds or more. For Intramuscular Use in Swine Only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

LincoMed 300 contains lincomycin hydrochloride, an antibiotic produced by Streptomyces lincolnensis var. lincolnensis which is chemically distinct from all other clinically available antibiotics and is isolated as a white crystalline solid.

INDICATIONS FOR SWINE:

LincoMed 300 is indicated for the treatment of infectious forms of arthritis caused by organisms sensitive to its activity. This includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, *Erysipelothrix* and *Mycoplasma* spp.

It is also indicated for the treatment of mycoplasma pneumonia.

CONTRAINDICATIONS:

As with all drugs, the use of LincoMed 300 is contraindicated in animals previously found to be hypersensitive to the drug.

Residue Warning: Swine intended for human consumption should not be slaughtered within 48 hours of latest treatment.

Human Warnings: Not for human use. Keep out of reach of children.

CAUTION:

If no improvement is noted within 48 hours, consult a veterinarian.

ADVERSE REACTIONS:

The intramuscular administration to swine may cause a transient diarrhea or loose stools. Although this effect has rarely been reported, one must be alert to the possibility that it may occur.

Should this occur, it is important that the necessary steps be taken to prevent the effects of dehydration.

The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION:

For arthritis or mycoplasma pneumonia - 5 mg/lb body weight intramuscularly once daily for three to seven days as needed. One mL per 60 lb body weight will provide 5 mg/lb.

For optimal results, initiate treatment as soon as possible.

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial closure prior to entry with a sterile needle and syringe. No vial closure should be entered more that 20 times.

Each mL contains:

Lincomycin hydrochloride equivalent to lincomycin 300mg; also benzyl alcohol 9.45 mg added as a preservative.

HOW SUPPLIED:

LincoMed is available in two concentrations: 100 mg/mL and 300 mg/mL.

300 mg/mL: For use in swine weighing 300 pounds or more. Supplied in 100 mL multiple dose vial.

100mg/mL: Supplied in 100 mL multiple dose vial.

Store at 20°C - 25°C (68°F - 77°F). Keep from freezing.



LINCOMED 300

lincomycin injection

Product	Information	

Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:61133-6001

Route of Administration INTRAMUSCULAR

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
Lincomycin (UNII: BOD072YW0F) (Lincomycin - UNII:BOD072YW0F)	Lincomycin	300 mg in 1 mL

P	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:61133-6001-1	100 mL in 1 VIAL, MULTI-DOSE			

Marketing End Date	ation Number or Monograph Marketing Start Citation Date	Marketing Application Number or Monograph Category Citation	
	368 08/02/2006	ANADA ANADA200368	ANADA

Labeler - Bimeda, Inc. (060492923)

Registrant - Bimeda, Inc. (060492923)

Establishment					
Name	Address	ID/FEI	Business Operations		
Bimeda-MTC		256232216	manufacture		

Revised: 3/2024 Bimeda, Inc.